MOLLI Surgical launches OncoPen, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer.
MOLLI
The sleek, pen-like wand seamlessly integrates with the MOLLI 2 System, offering tools for precisely targeting and removing cancerous lesions.
This wand is designed to offer surgeons unparalleled directional 3D guidance. Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience. The procedure involves pre-surgical placement of a tiny MOLLI Marker near the tumour. During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI Tablet to the precise location of the lesion. This precision allows for targeted lesion removal, smaller surgical incisions, conserving healthy tissue, and potentially improved cosmesis.
Dr. Jaime Alberty, director of The Comprehensive Breast Center at NYC Health + Hospitals/Kings County, shares enthusiastic insights into the impact of MOLLI Surgical's innovations in breast cancer surgery. Alberty said: "The OncoPen is truly exciting. The pen-like design complements our workflow seamlessly, further enhancing the capabilities of the MOLLI 2 System. This combination boosts my confidence in our ability to tackle cancer with unmatched precision. It's not just about technology; these tools empower us to deliver effective and compassionate care."
The increasing prevalence of breast cancer necessitates advancements in minimally invasive and patient-centric surgical techniques. OncoPen, designed for use with the MOLLI 2 System's advanced navigation capabilities, addresses this critical need.
"At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts," said Ananth Ravi, president and CEO of MOLLI Surgical. "We've dedicated ourselves to solving real clinical challenges, driven by a commitment to making a tangible difference in patient care. We're profoundly grateful for the opportunity to improve the patient experience and continue to advance the field of surgical oncology with our innovations."
Louise Temerty, breast cancer survivor and board member of MOLLI Surgical, said: “From the beginning, enhancing the patient experience with innovative surgical tools has been our guiding star. The OncoPen exemplifies this, leaving no scar behind — a symbol of our dedication to not just physical recovery, but emotional well-being too.”
